ProQR Therapeutics
PRQR
46 hedge funds and large institutions have $24.3M invested in ProQR Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.99% less ownership
Funds ownership: 26.15% → 23.16% (-3%)
10% less funds holding
Funds holding: 51 → 46 (-5)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
29% less capital invested
Capital invested by funds: $34.2M → $24.3M (-$9.91M)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
98% less call options, than puts
Call options by funds: $1K | Put options by funds: $57K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
Monaco Asset Management
Monaco
|
+$220K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$63.9K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$47.6K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$12.8K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$9.24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.06M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$624K |
| 3 |
Two Sigma Investments
New York
|
-$483K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$396K |
| 5 |
Two Sigma Advisers
New York
|
-$367K |
PRQR Hedge Fund Activity: Q3 2023 in Review
46 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q3 2023, worth a combined $24.3M — down 29% from $34.2M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PRQR and 4 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 8 added.
The largest buyer was Monaco Asset Management, adding an estimated $220K. The largest seller was Opaleye Management, exiting entirely with an estimated $1.06M sold.
- 46 institutional investors held ProQR Therapeutics (PRQR) as of Q3 2023, down from 51 in Q2 2023.
- Funds reported $24.3M of ProQR Therapeutics stock for Q3 2023, down 29% quarter-over-quarter.
- 4 funds opened new ProQR Therapeutics positions in Q3 2023 and 9 closed out, a net change of -5 holders.
- The largest ProQR Therapeutics buyer in Q3 2023 was Monaco Asset Management, an estimated $220K added.
- The largest ProQR Therapeutics seller in Q3 2023 was Opaleye Management, an estimated $1.06M sold.
Based on aggregated 13F filings for Q3 2023.